About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Neoadjuvant Carboplatin in Triple Negative Breast Cancer

NCT02978495·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Barretos Cancer Hospital

Age

18–any

Sex

FEMALE

Healthy volunteers

Accepted

You may be eligible if

Triple Negative Breast Cancer;
Stage II or III;
Performance Status ECOG \<2 or Karnofsky \>50%;
Hematologic (minimal values):
Absolute neutrophil count \> 1,500/mm3 Hemoglobin \> 10.0 g/dl Platelet count \> 100,000/mm3

You may not be if

Stage I or IV;
other malignancies.

The record

StatusCompleted

PhasePhase 2

Taking part154

StartedMay 2017

UpdatedDec 28, 2022

Conditions

BRCA1 Hereditary Breast and Ovarian Cancer Syndrome

Where1

Barretos Cancer Hospital
Barretos, São Paulo, Brazil

Clareo Health | Neoadjuvant Carboplatin in Triple Negative Breast Cancer